NEW MATERIAL:A neurotropic peptide derivative expressed by the formula (A6 is A5-Gln, etc.; A5 is A4-Ser, etc.; A4 is A3-Ile, etc.; A3 is A2-Asp, etc.; A2 is A1-Ala, etc.; A1 is X-D-Ala. X-Tyr, etc.; X is H, acyl, etc.; A7 is Trp-A8, etc.; A8 is Y, Ala-A9, etc.; A9 is Y, Gly-A10, etc.; A10 is Y, Pro-A11, etc.; A11 is Y or Leu-Y; Y is OH, amide residue or ester residue).
USE: A medicine for nervous degenerative diseases such as Alzheimer disease, Parkinson disease or amyotrophic lateral sclerosis.
PREPARATION: For example, a C-terminal amino acid having protected amino group is bound to an insoluble support with the carboxyl group thereof by a solid-phase method and the amino-protecting group is removed. Amino acids having protected amino groups are then bound according to the amino acid sequence of the objective peptide to synthesize the whole sequence. The resultant peptide is subsequently removed from the support to remove the protecting groups. Bondages, as necessary, are further formed between side chains to afford the objective peptide derivative.
FUKUSHIMA NOBUYUKI
IKEDA ZENJI
NISHIHARA NORIO
ONO KEIICHI
IRIE TSUNEMASA
KOJIKA YUKIO
YAMAMOTO MASAHIKO
Next Patent: PREPARATION OF BLOOD COAGULATION FACTOR VIII-VON-WILLEBRAND FACTOR COMPLEX CONCENTRATE FROM WHOLE BL...